Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma

2.1 Atezolizumab (Tecentriq, Roche) is indicated 'for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The NHS list price of atezolizumab (60 mg/ml) is £3,807.69 per 20‑ml vial. The NHS list price of bevacizumab (25 mg/ml) is £242.66 per 4‑ml vial and £924.40 per 16‑ml vial (excluding VAT; BNF online, accessed October 2020).

2.4 The company has commercial arrangements for atezolizumab and bevacizumab. These make atezolizumab plus bevacizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.